Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma

Detalhes bibliográficos
Autor(a) principal: Machado, Luiz S.
Data de Publicação: 2004
Outros Autores: Pedras, Dauro S.V., Antonucci, Jane B., Corbo, Rossana
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/2024
Resumo: Technetium-99m-methoxyisobutil isonitrila (99mTc-MIBI) has been introduced as a tumor-seeking agent in the past few years. The present study has evaluated the role of 99mTc-MIBI whole body scan (WBS) in localizing metastatic lesions by assessing sensitivity and specificity in comparison with 131I scan and serum thyroglobulin measurement. Eighty-nine thyroidectomized patients due to differentiated thyroid cancer were enrolled. Early (20 minutes) and delayed (6 and 24 hours) whole body images were obtained after 99mTc-MIBI injection. Tg measurements were obtained during thyroid hormone reposition and 4 weeks after hormone discontinuation, 131I scans were performed after low diagnostic or high ablative/therapeutic dose. These methods were used as standard to evaluate the presence of residual or metastatic thyroid cancer. The patients with 99mTc-MIBI scan positive and 131I negative scan underwent chest x-ray, computed tomography (CT) or magnetic resonance imaging (MRI). In the group with 131I negative scan (34/89), 23 patients presented 99mTc-MIBI WBS negative and 11 patients were discordant (specificity: 67,6%), and 22 patients had 99mTc-MIBI WBS and 131I scan positive; while the total of 131I scans positive was 55 (sensitivity: 40,0%). Eleven patients had 131I scan negative and 99mTc-MIBI WBS positive; seven of those proved to be true positive. Although 99mTc-MIBI has low sensitivity on detection of tumor recurrence, it may have a role as a supplementary tool to thyroglobulin measurements and 131I scans.
id INCA-1_f8dc6f43ff1511c03acd66e7501bf718
oai_identifier_str oai:rbc.inca.gov.br:article/2024
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinomaTecnécio-99M-MIBI no acompanhamento de carcinoma diferenciado de tireóideNeoplasias da tireóideCarcinomaCintilografiaTireoglobulinaMIBIThyroid neoplasmsCarcinomaRadionuclide imagingThyroglobulinMIBITechnetium-99m-methoxyisobutil isonitrila (99mTc-MIBI) has been introduced as a tumor-seeking agent in the past few years. The present study has evaluated the role of 99mTc-MIBI whole body scan (WBS) in localizing metastatic lesions by assessing sensitivity and specificity in comparison with 131I scan and serum thyroglobulin measurement. Eighty-nine thyroidectomized patients due to differentiated thyroid cancer were enrolled. Early (20 minutes) and delayed (6 and 24 hours) whole body images were obtained after 99mTc-MIBI injection. Tg measurements were obtained during thyroid hormone reposition and 4 weeks after hormone discontinuation, 131I scans were performed after low diagnostic or high ablative/therapeutic dose. These methods were used as standard to evaluate the presence of residual or metastatic thyroid cancer. The patients with 99mTc-MIBI scan positive and 131I negative scan underwent chest x-ray, computed tomography (CT) or magnetic resonance imaging (MRI). In the group with 131I negative scan (34/89), 23 patients presented 99mTc-MIBI WBS negative and 11 patients were discordant (specificity: 67,6%), and 22 patients had 99mTc-MIBI WBS and 131I scan positive; while the total of 131I scans positive was 55 (sensitivity: 40,0%). Eleven patients had 131I scan negative and 99mTc-MIBI WBS positive; seven of those proved to be true positive. Although 99mTc-MIBI has low sensitivity on detection of tumor recurrence, it may have a role as a supplementary tool to thyroglobulin measurements and 131I scans.Tecnécio-99m-metoxiisobutil isonitrila (99mTc-MIBI) foi, recentemente, introduzido como fármaco marcador-tumoral. Este estudo avalia o papel da cintilografia com 99mTc-MIBI na localização de lesões metastáticas através da análise de sua sensibilidade e especificidade, em comparação com rastreamento com 131I e níveis séricos de tireoglobulina. Foram estudados oitenta e nove pacientes tireoidectomizados por câncer diferenciado de tireóide. Foram adquiridas imagens de corpo inteiro precoces (20 minutos) e tardias (6 e 24 horas) após injeção de 99mTc- MIBI. Foram determinados os níveis séricos de tireoglobulina durante tratamento com hormônio tireoideano e 4 semanas após sua suspensão; rastreamento com 131I foi realizado após dose diagnóstica ou terapêutica/ablativa. Os pacientes que apresentaram resultados discordantes, foram submetidos a confirmação diagnóstica por tomografia computadorizada ou ressonância magnética. No grupo com rastreamento com 131I negativo (34/89), 23 pacientes apresentaram cintilografia com 99mTc-MIBI negativa e 11 pacientes tiveram resultado discordante (especificidade: 67,6%); 22 pacientes apresentaram cintilografia com 99mTc-MIBI e rastreamento com 131I positivas; enquanto o total de rastreamento com 131I positivos foi 55(sensibilidade: 40,0%). Onze pacientes apresentaram rastreamento com 131I e cintilografia com 99mTc-MIBI positiva; 7 destes pacientes foram comprovados como verdadeiros positivos; e quando associados os valores de tireoglobulina e os resultados encontrados pela cintilografia com 99mTc-MIBI, a sensibilidade passa a ser de 66,7% e a especificidade de 86,7%. Embora o 99mTc-MIBI apresente baixa sensibilidade na detecção de doença em atividade, o 99mTc-MIBI pode desempenhar papel importante como um método complementar aos valores de tireoglobulina e rastreamento com 131I.INCA2004-09-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/202410.32635/2176-9745.RBC.2004v50n3.2024Revista Brasileira de Cancerologia; Vol. 50 No. 3 (2004): July/Aug./Sept; 203-210Revista Brasileira de Cancerologia; Vol. 50 Núm. 3 (2004): jul./ago/sept.; 203-210Revista Brasileira de Cancerologia; v. 50 n. 3 (2004): jul./ago.set.; 203-2102176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/2024/1244Machado, Luiz S.Pedras, Dauro S.V.Antonucci, Jane B.Corbo, Rossanainfo:eu-repo/semantics/openAccess2021-11-29T20:32:45Zoai:rbc.inca.gov.br:article/2024Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:32:45Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
Tecnécio-99M-MIBI no acompanhamento de carcinoma diferenciado de tireóide
title Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
spellingShingle Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
Machado, Luiz S.
Neoplasias da tireóide
Carcinoma
Cintilografia
Tireoglobulina
MIBI
Thyroid neoplasms
Carcinoma
Radionuclide imaging
Thyroglobulin
MIBI
title_short Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
title_full Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
title_fullStr Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
title_full_unstemmed Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
title_sort Technetium-99m-MIBI in the follow-up of differentiated thyroid carcinoma
author Machado, Luiz S.
author_facet Machado, Luiz S.
Pedras, Dauro S.V.
Antonucci, Jane B.
Corbo, Rossana
author_role author
author2 Pedras, Dauro S.V.
Antonucci, Jane B.
Corbo, Rossana
author2_role author
author
author
dc.contributor.author.fl_str_mv Machado, Luiz S.
Pedras, Dauro S.V.
Antonucci, Jane B.
Corbo, Rossana
dc.subject.por.fl_str_mv Neoplasias da tireóide
Carcinoma
Cintilografia
Tireoglobulina
MIBI
Thyroid neoplasms
Carcinoma
Radionuclide imaging
Thyroglobulin
MIBI
topic Neoplasias da tireóide
Carcinoma
Cintilografia
Tireoglobulina
MIBI
Thyroid neoplasms
Carcinoma
Radionuclide imaging
Thyroglobulin
MIBI
description Technetium-99m-methoxyisobutil isonitrila (99mTc-MIBI) has been introduced as a tumor-seeking agent in the past few years. The present study has evaluated the role of 99mTc-MIBI whole body scan (WBS) in localizing metastatic lesions by assessing sensitivity and specificity in comparison with 131I scan and serum thyroglobulin measurement. Eighty-nine thyroidectomized patients due to differentiated thyroid cancer were enrolled. Early (20 minutes) and delayed (6 and 24 hours) whole body images were obtained after 99mTc-MIBI injection. Tg measurements were obtained during thyroid hormone reposition and 4 weeks after hormone discontinuation, 131I scans were performed after low diagnostic or high ablative/therapeutic dose. These methods were used as standard to evaluate the presence of residual or metastatic thyroid cancer. The patients with 99mTc-MIBI scan positive and 131I negative scan underwent chest x-ray, computed tomography (CT) or magnetic resonance imaging (MRI). In the group with 131I negative scan (34/89), 23 patients presented 99mTc-MIBI WBS negative and 11 patients were discordant (specificity: 67,6%), and 22 patients had 99mTc-MIBI WBS and 131I scan positive; while the total of 131I scans positive was 55 (sensitivity: 40,0%). Eleven patients had 131I scan negative and 99mTc-MIBI WBS positive; seven of those proved to be true positive. Although 99mTc-MIBI has low sensitivity on detection of tumor recurrence, it may have a role as a supplementary tool to thyroglobulin measurements and 131I scans.
publishDate 2004
dc.date.none.fl_str_mv 2004-09-30
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigos, Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2024
10.32635/2176-9745.RBC.2004v50n3.2024
url https://rbc.inca.gov.br/index.php/revista/article/view/2024
identifier_str_mv 10.32635/2176-9745.RBC.2004v50n3.2024
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/2024/1244
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 50 No. 3 (2004): July/Aug./Sept; 203-210
Revista Brasileira de Cancerologia; Vol. 50 Núm. 3 (2004): jul./ago/sept.; 203-210
Revista Brasileira de Cancerologia; v. 50 n. 3 (2004): jul./ago.set.; 203-210
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042248921120768